ES2728248T3 - Vacunas basadas en el virus paragripal 5 - Google Patents

Vacunas basadas en el virus paragripal 5 Download PDF

Info

Publication number
ES2728248T3
ES2728248T3 ES13741216T ES13741216T ES2728248T3 ES 2728248 T3 ES2728248 T3 ES 2728248T3 ES 13741216 T ES13741216 T ES 13741216T ES 13741216 T ES13741216 T ES 13741216T ES 2728248 T3 ES2728248 T3 ES 2728248T3
Authority
ES
Spain
Prior art keywords
piv5
virus
mice
influenza
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13741216T
Other languages
English (en)
Spanish (es)
Inventor
Biao He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia
University of Georgia Research Foundation Inc
Original Assignee
University of Georgia
University of Georgia Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia, University of Georgia Research Foundation Inc filed Critical University of Georgia
Application granted granted Critical
Publication of ES2728248T3 publication Critical patent/ES2728248T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18771—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES13741216T 2012-01-24 2013-01-24 Vacunas basadas en el virus paragripal 5 Active ES2728248T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261590070P 2012-01-24 2012-01-24
US201261590056P 2012-01-24 2012-01-24
US201261683810P 2012-08-16 2012-08-16
PCT/US2013/022962 WO2013112720A1 (en) 2012-01-24 2013-01-24 Parainfluenza virus 5 based vaccines

Publications (1)

Publication Number Publication Date
ES2728248T3 true ES2728248T3 (es) 2019-10-23

Family

ID=48873896

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13741216T Active ES2728248T3 (es) 2012-01-24 2013-01-24 Vacunas basadas en el virus paragripal 5

Country Status (13)

Country Link
US (6) US9732358B2 (enExample)
EP (2) EP2806891B1 (enExample)
JP (3) JP6228136B2 (enExample)
CN (2) CN104093422B (enExample)
AU (1) AU2013212097B2 (enExample)
BR (1) BR112014018179B1 (enExample)
CA (2) CA2860388C (enExample)
ES (1) ES2728248T3 (enExample)
MX (1) MX359638B (enExample)
MY (1) MY173638A (enExample)
PH (1) PH12014501255B1 (enExample)
PT (1) PT2806891T (enExample)
WO (2) WO2013112720A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649371B2 (en) 2011-02-25 2017-05-16 University Of Georgia Research Foundation, Inc. Recombinant mumps virus vaccine
MY173638A (en) 2012-01-24 2020-02-12 Univ Georgia Parainfluenza virus 5 based vaccines
KR101577397B1 (ko) * 2014-01-15 2015-12-28 경북대학교 산학협력단 신규한 돼지 파라인플루엔자 바이러스 5(pPIV5), 이를 포함하는 백신 조성물 및 이를 이용한 돼지 파라인플루엔자 바이러스 검정 키트
WO2016176510A1 (en) 2015-04-28 2016-11-03 University Of Georgia Research Foundation, Inc. Piv5-based amplifying virus-like particles
JPWO2016199936A1 (ja) * 2015-06-12 2018-04-05 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
CA3064897A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
RU2681473C1 (ru) * 2018-01-16 2019-03-06 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для обнаружения генома вируса парагриппа 3 типа у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
WO2020092207A1 (en) * 2018-10-28 2020-05-07 University Of Georgia Research Foundation Broadly reactive immunogens of influenza virus, compositions, and methods of use thereof
CL2018003869A1 (es) 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
AU2021342576A1 (en) * 2020-09-21 2023-04-06 University Of Georgia Research Foundation, Inc. PIV5-based covid-19 vaccine
US20240102912A1 (en) * 2020-11-09 2024-03-28 Thrive Bioscience, Inc. Plaque counting assay method
CN113005149A (zh) * 2021-03-26 2021-06-22 中国农业大学 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
CN118019854A (zh) * 2021-08-26 2024-05-10 乔治亚大学研究基金公司 J副粘病毒疫苗
AU2022347195A1 (en) * 2021-09-20 2024-05-02 Cyanvac Llc Piv5-based coronavirus vaccines and methods of use thereof
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors
CN120456918A (zh) * 2022-11-04 2025-08-08 蓝湖生物科技股份公司 重组rsv疫苗：制备和使用其的方法
CN121263205A (zh) * 2023-02-06 2026-01-02 塞维卡有限责任公司 修饰的piv5疫苗载体：制造方法和用途
CN116270766A (zh) * 2023-02-23 2023-06-23 天津理工大学 一种副流感病毒5型作为溶瘤病毒在抗肿瘤中的应用
CN117625560B (zh) * 2023-11-03 2025-09-16 中国农业大学 一种重组病毒rPIV5-H3及其制备方法、应用和疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
CA2160038A1 (en) * 1995-07-14 1997-01-15 Biosignal Inc. Methods of screening compounds for their pharmacological relevance based on downregulation of recombinant receptors
AU2749297A (en) 1996-05-01 1997-11-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Generation of viral transfectants using recombinant DNA-derived nucleoc apsid proteins
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
EP1179054A2 (en) 1999-12-10 2002-02-13 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
JP2002153278A (ja) 2000-11-22 2002-05-28 Hisamitsu Pharmaceut Co Inc ウイルスベクターの製造に用いられる細胞、その製法およびその細胞を用いたウイルスベクターの製造方法
US20050048030A1 (en) * 2001-09-28 2005-03-03 Raymond Pickles Paramyxoviruses as gene transfer vectors to lung cells
US7585667B2 (en) * 2003-06-13 2009-09-08 The United States Of America As Represented By The Department Of Health And Human Services Negative strand RNA virus replicon
PT2540312E (pt) * 2007-07-19 2015-08-31 Novavax Inc Vlps quiméricas de gripe aviária
US20090208495A1 (en) 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
FR2938840B1 (fr) 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
MY173638A (en) 2012-01-24 2020-02-12 Univ Georgia Parainfluenza virus 5 based vaccines

Also Published As

Publication number Publication date
WO2013112720A1 (en) 2013-08-01
US11542527B2 (en) 2023-01-03
EP2806891A4 (en) 2015-08-26
US10329585B2 (en) 2019-06-25
US20150086588A1 (en) 2015-03-26
WO2013112690A1 (en) 2013-08-01
BR112014018179A2 (pt) 2017-07-04
US9505807B2 (en) 2016-11-29
US9732358B2 (en) 2017-08-15
MX359638B (es) 2018-10-04
PH12014501255B1 (en) 2019-10-16
US20140370050A1 (en) 2014-12-18
CN104093422B (zh) 2018-02-23
JP2018050624A (ja) 2018-04-05
PH12014501255A1 (en) 2014-09-08
CN108130345A (zh) 2018-06-08
EP2806891B1 (en) 2019-04-10
JP2020014470A (ja) 2020-01-30
MY173638A (en) 2020-02-12
JP6900437B2 (ja) 2021-07-07
CA2860388C (en) 2021-10-26
US20190284578A1 (en) 2019-09-19
JP6228136B2 (ja) 2017-11-08
EP3536341A1 (en) 2019-09-11
AU2013212097B2 (en) 2017-01-12
US20170067080A1 (en) 2017-03-09
US10752916B2 (en) 2020-08-25
US20170327845A1 (en) 2017-11-16
EP2806891A1 (en) 2014-12-03
CA3128591A1 (en) 2013-08-01
MX2014008557A (es) 2014-10-24
US20200377908A1 (en) 2020-12-03
PT2806891T (pt) 2019-07-01
CA2860388A1 (en) 2013-08-01
JP2015506689A (ja) 2015-03-05
BR112014018179B1 (pt) 2022-04-12
AU2013212097A1 (en) 2014-06-26
CN104093422A (zh) 2014-10-08

Similar Documents

Publication Publication Date Title
US11542527B2 (en) Parainfluenza virus 5 based vaccines
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
ES2929942T3 (es) Vacunas contra el virus de la gripe y sus usos
Zhang et al. Hemagglutinin glycosylation modulates the pathogenicity and antigenicity of the H5N1 avian influenza virus
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
Le et al. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus
US20250186578A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
US20260034205A1 (en) Modified live attenuated flu virus vaccines and uses thereof
Baker The Packaging Signals of Influenza A and B Viruses Contribute to Their Speciation and Can Be Manipulated for Novel Vaccine Development
Jingjiao et al. Newcastle disease virus-based H5 influenza vaccine protects chickens from lethal challenge with a highly pathogenic H5N2 avian influenza virus
CN118019854A (zh) J副粘病毒疫苗